Collectively, our data show that use of autologous T cells can be a remarkably potent vaccine strategy by delivering antigens and adjuvant signals to lymphoid tissues to activate host DCs and promote strong antigen-specific CD8+ and CD4+ responses to tumor antigens, which can mediate clinical effects in murine models. Here, CD8A is linked to neoplasm.